Newswise — New Brunswick, N.J., August 28, 2014 – The remodeling of a kitchen or bathroom changes the appearance of the room and improves its functionality. As investigators at Rutgers Cancer Institute of New Jersey and Rutgers and Princeton Universities have demonstrated, a similar concept comes into play in remodeling proteins found within a family of cancers that does not respond well to cancer-treating drugs -- cancers driven by what is known as activated Ras.
According to the National Cancer Institute, more than a third of all human cancers are driven by mutations in the Ras family of genes. When Ras is activated, it promotes tumor growth but also activates autophagy which helps to sustain that growth. These cancers remodel proteins using the cellular self-cannibalization process known as autophagy to capture and degrade intracellular proteins and protein-containing organelles. Since Ras-driven cancers often rely on autophagy for growth and survival, this raised the question: Is proteome remodeling by autophagy important, and if so, by what mechanism?
This question was answered in research published in the current online edition of Molecular Cell (doi: 10.1016/j.molcel.2014.07.019), by senior author Eileen White, PhD, associate director for basic science at the Cancer Institute of New Jersey, and colleagues. They compared the global proteome (all of the expressed proteins) of Ras-driven cancer cells where autophagy was present to those where autophagy was deficient.
In this latest study researchers found that autophagy affects a majority of the proteins in Ras-driven cancers, yet the process is highly selective as to which proteins are targeted. For instance, investigators found that autophagy eliminates proteins involved in non-essential pathways or those deemed toxic under stressful conditions. Meanwhile, autophagy-resistant proteins involved in pathways needed for stress survival and autophagy maintenance were spared. The authors say these sets of proteins can serve as biomarkers for monitoring autophagy in the clinical setting. The study also revealed that defects in the autophagy process caused accumulation of certain proteins that prompted activation of an immune response in cancer cells and led to cell death.
“This remodeling process of the cell proteome by autophagy is an important immune-suppressive survival mechanism for Ras-driven cancers, and inhibiting autophagy can provide a means to target these aggressive cancers,” notes White, who is also a distinguished professor of molecular biology and biochemistry at Rutgers School of Arts and Sciences.
Along with White, other authors on the study are: Robin Mathew and Sinan Khor, both Cancer Institute and Rutgers University; Sean Hackett, Princeton University; Joshua D. Rabinowitz, Princeton University and Cancer Institute; and David H. Perlman, Princeton University.
The work was supported by funding from the National Institutes of Health (R37 CA53370 and R01 CA130893, White; RC1 CA147961 and R01 CA163591, White, Rabinowitz), and the Department of Energy (DE-AC05-06OR23100, Hackett).
About Rutgers Cancer Institute of New JerseyRutgers Cancer Institute of New Jersey (www.cinj.org) is the state’s first and only National Cancer Institute-designated Comprehensive Cancer Center. As part of Rutgers, The State University of New Jersey, the Cancer Institute of New Jersey is dedicated to improving the detection, treatment and care of patients with cancer, and to serving as an education resource for cancer prevention. Physician-scientists at the Cancer Institute engage in translational research, transforming their laboratory discoveries into clinical practice, quite literally bringing research to life. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 732-235-8614 or visit www.cinj.org/giving. Follow us on Facebook at www.facebook.com/TheCINJ.
The Cancer Institute of New Jersey Network is comprised of hospitals throughout the state and provides the highest quality cancer care and rapid dissemination of important discoveries into the community. Flagship Hospital: Robert Wood Johnson University Hospital. System Partner: Meridian Health (Jersey Shore University Medical Center, Ocean Medical Center, Riverview Medical Center, Southern Ocean Medical Center, and Bayshore Community Hospital). Major Clinical Research Affiliate Hospitals: Carol G. Simon Cancer Center at Morristown Medical Center, Carol G. Simon Cancer Center at Overlook Medical Center, and Cooper University Hospital. Affiliate Hospitals: JFK Medical Center, Robert Wood Johnson University Hospital Hamilton (CINJ Hamilton), Robert Wood Johnson University Hospital Somerset and University Medical Center of Princeton at Plainsboro.